GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Cash position of $238.1 million as of June 30, 2023
- Belief that existing cash will be sufficient to fund operations until 2026
- Net loss of $7.7 million for Q2 2023 compared to net profit of $0.3 million in Q2 2022
- GH001 clinical trial for treatment-resistant depression underway, expected to enroll approximately 80 patients
- GH001 clinical trial for postpartum depression expected to be completed in Q4 2023
- GH001 clinical trial for bipolar II disorder recruiting slower than projected, now expected to be completed in Q1 2024
- GH002 clinical trial in healthy volunteers expected to be completed in Q4 2023
- Appointment of Velichka Valcheva as VP Clinical Research and Medical Affairs
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.
Second Quarter 2023 Financial Highlights
Cash position
Cash, cash equivalents, other financial assets and marketable securities were
Research and development expenses
R&D expenses were
General and administrative expenses
G&A expenses were
Net loss
Net loss was
Business Updates
GH001
GH001, our proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, is currently being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in patients with treatment-resistant depression (TRD) (GH001-TRD-201). Patient enrollment for this trial is underway, with expected recruitment of approximately 80 patients across several European countries. The primary objective is to determine the efficacy of our single-day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) at the end of the 7-day double-blind phase. The double-blind phase is followed by a 6-month open-label extension phase where all patients can receive treatment with the GH001 IDR as-needed, based on the patient’s clinical status. Further trial design details are described in our corporate presentation, which is available in the investor section on our website.
As previously announced, we expect to submit an IND with the U.S. FDA for GH001 in TRD, delivered with our proprietary aerosol delivery device, in the third quarter of 2023. Pending clearance by the FDA, we expect to initiate a Phase 1 clinical pharmacology trial of GH001 delivered with our proprietary aerosol delivery device in healthy volunteers (GH001-HV-106) in the fourth quarter of 2023. The trial is designed to support bridging to the clinical data generated with the third-party device we currently use in our clinical trials.
Our Phase 2a proof-of-concept clinical trial of GH001 in postpartum depression (GH001-PPD-203) is ongoing and, as previously announced, is expected to be completed in the fourth quarter of 2023. Our Phase 2a proof-of-concept clinical trial of GH001 in bipolar II disorder with a current depressive episode (GH001-BD-202) is recruiting slower than previously projected and we now expect this trial to be completed in the first quarter of 2024.
GH002
As previously announced, our randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002, our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intravenous approach, in healthy volunteers (GH002-HV-105) is expected to be completed in the fourth quarter of 2023.
Expansion of Executive Management Team
We are pleased to announce the recent expansion of our Executive Management Team, with the appointment of Velichka (Villy) Valcheva, MD, MSc as VP Clinical Research and Medical Affairs. Villy has more than 20 years’ experience in various leadership roles, with global exposure in pharmaceutical and biotech companies, including Global Senior Medical Director positions at Ipsen and Sanofi. Villy joins us from Albireo, where, in her position as VP and Head of Medical Affairs International, she was responsible for all international medical activities, played a pivotal role in gaining market access across multiple countries, was deeply involved in driving the company’s strategic decisions, and significantly contributed to the recent acquisition of Albireo by Ipsen.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
GH Research PLC's annual report on Form 20-F/A filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2022 is available at www.ghres.com and shareholders may receive a hard copy free of charge upon request.
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where
About GH002 and GH003
GH002 is our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intravenous approach. GH002 is currently in Phase 1 clinical development. GH003 is our mebufotenin (5-MeO-DMT) product candidate formulated for administration via a proprietary intranasal administration approach. GH003 is currently in preclinical development. We anticipate developing GH002 and GH003 in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.
Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, medical devices required to deliver these product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, cash runway, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com
| GH RESEARCH PLC Condensed Consolidated Interim Statement of Comprehensive Income (Unaudited) (in thousands, except share and per share amounts) | |||||
| Three months ended June 30, | Six months ended June 30, | ||||
| 2023 | 2022 | 2023 | 2022 | ||
| $’000 | $’000 | $’000 | $’000 | ||
| Operating expenses | |||||
| Research and development | (7,176) | (4,240) | (14,482) | (8,954) | |
| General and administration | (2,749) | (2,510) | (5,862) | (5,802) | |
| Loss from operations | (9,925) | (6,750) | (20,344) | (14,756) | |
| Finance income | 2,122 | - | 3,611 | - | |
| Finance expense | (179) | - | (350) | - | |
| Movement of expected credit loss | 217 | - | 18 | - | |
| Foreign exchange gain/(loss) | 36 | 7,084 | (1,601) | 9,327 | |
| Total other income | 2,196 | 7,084 | 1,678 | 9,327 | |
| (Loss)/profit before tax | (7,729) | 334 | (18,666) | (5,429) | |
| Tax charge/(credit) | - | - | - | - | |
| (Loss)/profit for the period | (7,729) | 334 | (18,666) | (5,429) | |
| Other comprehensive (expense)/income | |||||
| Items that may be reclassified to profit or loss | |||||
| Fair value movement on marketable securities | (1,512) | - | (788) | - | |
| Currency translation adjustment | (57) | (7,054) | 1,619 | (9,315) | |
| Total comprehensive loss for the period | (9,298) | (6,720) | (17,835) | (14,744) | |
| Attributable to owners: | |||||
| (Loss)/profit for the period | (7,729) | 334 | (18,666) | (5,429) | |
| Total comprehensive loss for the period | (9,298) | (6,720) | (17,835) | (14,744) | |
| (Loss)/earnings per share | |||||
| Basic and diluted (loss)/earnings per share (in USD) | (0.15) | 0.01 | (0.36) | (0.10) | |
| GH RESEARCH PLC Condensed Consolidated Interim Balance Sheet (Unaudited) (in thousands) | |||
| At June 30, | At December 31, | ||
| 2023 | 2022 | ||
| $’000 | $’000 | ||
| ASSETS | |||
| Current assets | |||
| Cash and cash equivalents | 96,895 | 165,955 | |
| Other financial assets | 54,728 | - | |
| Marketable securities | 13,761 | - | |
| Other current assets | 1,015 | 2,586 | |
| Total current assets | 166,399 | 168,541 | |
| Non-current assets | |||
| Marketable securities | 72,697 | 85,724 | |
| Property, plant, and equipment | 1,176 | 97 | |
| Total non-current assets | 73,873 | 85,821 | |
| Total assets | 240,272 | 254,362 | |
| LIABILITIES AND EQUITY | |||
| Current liabilities | |||
| Trade payables | 2,912 | 1,868 | |
| Lease liability | 267 | - | |
| Other current liabilities | 3,378 | 2,678 | |
| Total current liabilities | 6,557 | 4,546 | |
| Non-current liabilities | |||
| Lease liability | 732 | - | |
| Total non-current liabilities | 732 | - | |
| Total liabilities | 7,289 | 4,546 | |
| Equity attributable to owners | |||
| Share capital | 1,301 | 1,301 | |
| Additional paid-in capital | 291,448 | 291,448 | |
| Other reserves | 2,809 | 2,595 | |
| Foreign currency translation reserve | (11,416) | (13,035) | |
| Accumulated deficit | (51,159) | (32,493) | |
| Total equity | 232,983 | 249,816 | |
| Total liabilities and equity | 240,272 | 254,362 | |
